Abstract
Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases. Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide. Stem cell transplantation (SCT) has been widely adopted in CR2, but optimal SCT (auto- or allo-SCT) remains controversial. We analyzed the outcomes for 8 APL patients initially treated using ATRA, who relapsed, achieved CR2 and underwent auto-SCT (n = 4) or allo-SCT (n = 4). The mean age of patients who underwent allo-SCT was 39 years. Minimal residual disease (MRD) just prior to SCT was positive in 1 patient and negative in 3. Engraftment was achieved in all patients, but 2 patients died of transplantation-related complications within 6 months. Complete molecular remission has been maintained in the remaining 2 patients. The mean age of patients who underwent auto-SCT was 48 years. MRD just prior to SCT was negative in all 4 patients. Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months). The results for auto-SCT are favorable in patients with MRD-negative APL.
| Original language | English |
|---|---|
| Pages (from-to) | 1095-1099 |
| Number of pages | 5 |
| Journal | [Rinshō ketsueki] The Japanese journal of clinical hematology |
| Volume | 46 |
| Issue number | 10 |
| Publication status | Published - 2005 |
| Externally published | Yes |
Fingerprint
Cite this
Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid. / Fujita, Hiroyuki; Nakaya, Aya; Kato, Jun; Tachibana, Takayoshi; Takemura, Sachiya; Hyo, Rie; Kawano, Tomoko; Tanaka, Masatsugu; Taguchi, Jun; Maruta, Atsuo; Fujimaki, Katsumichi; Kanamori, Heiwa; Ishigatsubo, Yoshiaki.
In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 46, No. 10, 2005, p. 1095-1099.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid
AU - Fujita, Hiroyuki
AU - Nakaya, Aya
AU - Kato, Jun
AU - Tachibana, Takayoshi
AU - Takemura, Sachiya
AU - Hyo, Rie
AU - Kawano, Tomoko
AU - Tanaka, Masatsugu
AU - Taguchi, Jun
AU - Maruta, Atsuo
AU - Fujimaki, Katsumichi
AU - Kanamori, Heiwa
AU - Ishigatsubo, Yoshiaki
PY - 2005
Y1 - 2005
N2 - Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases. Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide. Stem cell transplantation (SCT) has been widely adopted in CR2, but optimal SCT (auto- or allo-SCT) remains controversial. We analyzed the outcomes for 8 APL patients initially treated using ATRA, who relapsed, achieved CR2 and underwent auto-SCT (n = 4) or allo-SCT (n = 4). The mean age of patients who underwent allo-SCT was 39 years. Minimal residual disease (MRD) just prior to SCT was positive in 1 patient and negative in 3. Engraftment was achieved in all patients, but 2 patients died of transplantation-related complications within 6 months. Complete molecular remission has been maintained in the remaining 2 patients. The mean age of patients who underwent auto-SCT was 48 years. MRD just prior to SCT was negative in all 4 patients. Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months). The results for auto-SCT are favorable in patients with MRD-negative APL.
AB - Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases. Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide. Stem cell transplantation (SCT) has been widely adopted in CR2, but optimal SCT (auto- or allo-SCT) remains controversial. We analyzed the outcomes for 8 APL patients initially treated using ATRA, who relapsed, achieved CR2 and underwent auto-SCT (n = 4) or allo-SCT (n = 4). The mean age of patients who underwent allo-SCT was 39 years. Minimal residual disease (MRD) just prior to SCT was positive in 1 patient and negative in 3. Engraftment was achieved in all patients, but 2 patients died of transplantation-related complications within 6 months. Complete molecular remission has been maintained in the remaining 2 patients. The mean age of patients who underwent auto-SCT was 48 years. MRD just prior to SCT was negative in all 4 patients. Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months). The results for auto-SCT are favorable in patients with MRD-negative APL.
UR - http://www.scopus.com/inward/record.url?scp=33644886338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644886338&partnerID=8YFLogxK
M3 - Article
C2 - 16440769
AN - SCOPUS:33644886338
VL - 46
SP - 1095
EP - 1099
JO - [Rinshō ketsueki] The Japanese journal of clinical hematology
JF - [Rinshō ketsueki] The Japanese journal of clinical hematology
SN - 0485-1439
IS - 10
ER -